COVID-19 Clinical Trial
Official title:
Profile of COVID-19 Patients Related to Fatigue
More than half of recovered COVID-19 patients experience fatigue. Studies are needed to define the profile of these patients. The objective of this study is to evaluate the profile of surviving patients of COVID-19 in relation to fatigue.
Status | Recruiting |
Enrollment | 398 |
Est. completion date | December 31, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of COVID-19 - adults (>18 years) - basic knowledge and access to the internet - wish to participate in the study and sign the informed consent Exclusion Criteria: - patients with severe comorbidities that interfere with the ability to perform the study, and those with mental, physical or organic problems that under medical criteria may pose a risk to the patient |
Country | Name | City | State |
---|---|---|---|
Spain | University of Granada | Granada |
Lead Sponsor | Collaborator |
---|---|
Universidad de Granada |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perceived Fatigue | To assess perceived fatigue using the borg modified scale. Scale ranges from 0 to 10, with higher punctuation indicating higher fatigue perception. | Through study completion, an average of 1 year | |
Primary | Multidimensional Fatigue | To assess multidimensional fatigue using the multidimensional fatigue inventory | Through study completion, an average of 1 year | |
Primary | Fatigue Severity | To assess fatigue severity using the fatigue severity scale. The total score ranges from 7 to 63 points, with higher punctuation indicating higher fatigue severity | Through study completion, an average of 1 year | |
Primary | Fatigue Impact | To assess fatigue impact using the modified fatigue impact scale. All items are scaled so that higher scores indicate a greater impact of fatigue on a person's activities. This scale can range from 0 to 36. | Through study completion, an average of 1 year | |
Primary | Muscular Fatigue | To assess muscular fatigue using surface electromyography | Through study completion, an average of 1 year | |
Secondary | COVID-19 information | To assess information about the date and symptoms when COVID-19 was diagnosed | Through study completion, an average of 1 year | |
Secondary | Dyspnea | To assess Dyspnea perception using the borg modified scale | Through study completion, an average of 1 year | |
Secondary | Cough | To assess cough using the leicester cough questionnaire | Through study completion, an average of 1 year | |
Secondary | Pain intensity | To assess pain intensity using the visual analogue scale and brief pain inventory | Through study completion, an average of 1 year | |
Secondary | Functional status | To assess functional status using the post-covid functional scale and functional independence measure | Through study completion, an average of 1 year | |
Secondary | Frailty | To assess frailty using the clinical frailty scale | Through study completion, an average of 1 year | |
Secondary | Health-related Quality of life | To assess health-related quality of life using the euroqol-5d | Through study completion, an average of 1 year | |
Secondary | Psychological status | To assess Psychological status using the hospital anxiety and depression scale | Through study completion, an average of 1 year | |
Secondary | Sleep quality | To assess sleep quality using the Pittsburgh Sleep Quality Index | Through study completion, an average of 1 year | |
Secondary | Nutritional status | To assess nutritional status using the mini nutritional assessment | Through study completion, an average of 1 year | |
Secondary | Physical activity | To assess physical activity using the international physical activity questionnaire. This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in Metabolic Equivalent (MET)-min/week and time spent sitting. | Through study completion, an average of 1 year | |
Secondary | Kinesiophobia | To assess kinesiophobia using the TAMPA scale | Through study completion, an average of 1 year | |
Secondary | Exercise capacity | To assess exercise capacity using the Short Physical Performance Battery and the 6 minutes walk test | Through study completion, an average of 1 year | |
Secondary | Strength | To assess strength using dynamometry | Through study completion, an average of 1 year | |
Secondary | Heart rate variability | To assess heart rate variability using holter | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|